neonatal haemochromatosis
Conditions
Interventions
The treatment consisted of intravenous immunoglobulin administered weekly at a dose of 1 g per kg bodyweight from the 18th week until the end of gestation.
Sponsors
Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women who were pregnant were identified as candidates for treatment if they had a previous infant or fetus affected with neonatal hemochromatosis and, therefore, were considered to be at high risk to have another.
Exclusion criteria
Exclusion criteria: Women who had allergy for immunoglobulin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the effectiveness in preventing the severity of recurrent neonatal haemochromatosis: monitoring of the mother's health and the progress of pregnanacy monitering of the infant's health, liver function and development | — |
Countries
Japan
Contacts
Public ContactYusuke Mitani
School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Department of Pediatrics
Outcome results
None listed